FLASH MONITORING IS A CLINICALLY EFFECTIVE METHOD FOR ACHIEVING COMPENSATION FOR DIABETES MELLITUS TYPE 1

DOI: https://doi.org/10.29296/24999490-2020-05-04

Y.G. Samoilova(1), M.V. Koshmeleva(1), O.A. Oleynik(1), T.A. Filippova(1), I.V. Tolmachev(1), D.A. Kudlay(2, 3), V.E. Mutalimi(1), N.V. Bolotova(4) 1-Siberian State Medical University, Moskovsky trakt, 2, Tomsk, 634050, Russian Federation; 2-NRC Institute of Immunology FMBA of Russia, Kashirskoye highway, 24, Moscow, 115522, Russian Federation; 3-I.M. Sechenov First Moscow State Medical University, Trubetskaya street, 8, bldg. 2, Moscow, 119991, Russian Federation; 4-Saratov State Medical University named after V.I. Razumovsky, Bolshaya Kazachia street, 112, Saratov, 410012, Russian Federation E-mail: [email protected]

Introduction. Continuous glucose monitoring (СGM) is currently one of the most promising methods for controlling type 1 diabetes (T1D). Flash monitoring is the most relevant and promising direction in diabetology, which allows to monitor the level of glycemia an unlimited number of times and, as well as does not require calibration of the device. The aim of the study: to evaluate the clinical and metabolic effectiveness of flash monitoring of glycemia in patients with T1D. Methods. The study included 80 patients with T1D on various insulin therapy regimens. All patients were tested for glycated hemoglobin (HbA1c), flash glycemia monitoring, and quality of life assessment using the MOS SF 36 and PedsQl Diabetic module 3.2 questionnaires. Based on the glycemic charts were evaluated: the average level of glycemia (mmol/l), time of blood glucose above target value (%), time of glucose within target values (time in range), time of blood glucose below target values (%), frequency of Hypo – and hyperglycemia (episodes per week), the average daily dose of insulin (U/l). Results. HbA1c decreased by 1.6% (p
Keywords: 
type 1 diabetes, flash monitoring, quality of life, pump insulin therapy

Список литературы: 
  1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352 (9131): 837–53. https://doi.org/10.1016/S0140-6736(98)07019-6
  2. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005; 353 (25): 2643–53. https://doi.org/10.1056/NEJMoa052187
  3. Orchard T.J., Nathan D.M., Zinman B., Cleary P., Brillon D., Backlund J.Y., Lachin J.M. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015; 313 (1): 45–53. https://doi.org/10.1001/jama.2014.16107.
  4. Samojlova Ju.G., Rotkank M.A., Zhukova N.G., Matveeva M.V., Tolmachev I.V., Kudlaj D.A. Variabel'nost' glikemii u patsientov s saharnym diabetom 1-go tipa: svjaz' s kognitivnoj disfunktsiej i dannymi magnitno-rezonansnyh metodov issledovanija. Problemy Endokrinologii. 2018; 64 (5): 286–91. [Samojlova Y.G., Rotkank M.A., Zhukova N.G., Matveeva M.V., Tolmachev I.V., Kudlaj D.A. Variabel’nost’ glikemii u pacientov s saharnym diabetom 1-go tipa: svjaz’ s kognitivnoj disfunkciej i dannymi magnitno-rezonansnyh metodov issledovanija. Problemy Jendokrinologii. 2018; 64 (5): 286–91 (in Russian)]
  5. Algoritmy spetsializirovannoj meditsinskoj pomoschi bol'nym saharnym diabetom: klinicheskie rekomendatsii. Pod red. I.I. Dedova, M.V. Shestakovoj, A.Ju. Majorova. Saharnyj diabet. 2017; 20 (1S, vyp. 8): 1–121. [Algoritmy specializirovannoj medicinskoj pomoshhi bol’nym saharnym diabetom: klinicheskie rekomendacii / pod red. I.I. Dedova, M.V. Shestakovoj, A.Ju. Majorova // Saharnyj diabet. 2017. T. 20, № 1S, Vyp. 8. S. 1–121 (in Russian)]
  6. Samojlova Ju.G., Rotkank M.A., Zhukova N.G., Matveeva M.V., Tolmachev I.V., Kudlaj D.A. Markery kognitivnyh narushenij i variabel'nost' glikemii u patsientov s saharnym diabetom 1-go tipa. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2018; 118 (4): 48–51. [Samojlova Y.G., Rotkank M.A., Zhukova N.G., Matveeva M.V., Tolmachev I.V., Kudlaj D.A. Markery kognitivnyh narushenij i variabel’nost’ glikemii u pacientov s saharnym diabetom 1-go tipa. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2018; 118 (4): 48–51 (in Russian)].
  7. Samojlova Ju.G., Rotkank M.A., Zhukova N.G., Matveeva M.V., Tolmachev I.V., Tonkih O.S., Kudlaj D.A. Primenenie magnitno-rezonansnyh metodov issledovanija golovnogo mozga u patsientov s saharnym diabetom 1-go tipa i kognitivnoj disfunktsiej. Nevrologicheskij zhurnal. 2018; 23 (2): 86–92. [Samojlova Y.G., Rotkank M.A., Zhukova N.G., Matveeva M.V., Tolmachev I.V., Tonkih O.S., Kudlaj D.A. Primenenie magnitno-rezonansnyh metodov issledovanija golovnogo mozga u pacientov s saharnym diabetom 1-go tipa i kognitivnoj disfunkciej. Nevrologicheskij zhurnal. 2018; 23 (2): 86–92 (in Russian)].
  8. Davis W.A., Davis T.M. Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res. Clin. Pract. 2010; 90: 75–8.
  9. Dean J. Organising care for people with diabetes and renal disease. J. Ren. Care. 2012; 38 (1): 23–9.
  10. Eeg-Olofsson K., Cederholm J., Nilsson P.M. et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care. 2010; 33: 1640–6.
  11. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2017; 40 (1): 1–135.
  12. Koshmeleva M.V., Ju.G. Samojlova, O.S. Kobjakova, D.A. Kudlaj, O.A. Olejnik, M.V. Matveeva, T.A. Filippova, I.V Tolmachev Opyt primenenija tehnologij distantsionnogo monitoringa saharnogo diabeta 1-go tipa na etape ambulatornogo zvena zdravoohranenija Pediatrija. 2019; 98 (5): 219–24. [Koshmeleva M.V., Samojlova Y.G., O.S. Kobjakova, D.A. Kudlaj, O.A. Olejnik, M.V. Matveeva, T.A. Filippova, I.V Tolmachev Opyt primenenija tehnologij distancionnogo monitoringa saharnogo diabeta 1-go tipa na jetape ambulatornogo zvena zdravoohranenija Pediatrija. 2019; 98 (5): 219–24 (in Russian)]
  13. Raccah D., Sulmont V., Reznik Y. et al. In?cremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The Real Trend study. Diabetes Care. 2009; 32 (12): 2245–50.
  14. Bolinder J., Antuna R., Geelhoed-Duijvestijn P. et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388 (10057): 2254–63.
  15. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care. 2010; 33: 17–22.
  16. Battelino T., Conget I., Olsen B. et al. SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55: 3155–62.
  17. Riveline J.P., Schaepelynck P., Chaillous L. et al. EVADIAC Sensor Study Group. Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. Diabetes Care. 2012; 35: 965–71.
  18. Skyler J.S. Diabetic complications. The importance of glucose control. Endocrinol. Metab. Clin. North Am. 1996; 25 (2): 243–54.
  19. Ware J.E., Kosinski M., Keller S.D. SF-36 physical and mental health summary scales: a user’s manual. New England Medical Center Hospital; Health Institute. 5-th print. Boston, 1994.
  20. Varni J., Seid M., Kurtin P. The PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med. Care. 2001; 39: 800–12.
  21. Nikitina T.P., Kishtovich A.V., Moiseenko E.I. i dr. Issledovanie kachestva zhizni v pediatrii: razrabotka russkoj versii oprosnika PedsQL 4.0 Generic Core Scales dlja otsenki kachestva zhizni detej 8–12 let. Vestnik Mezhnatsional'nogo tsentra issledovanija kachestva zhizni. 2003; 1: 35–44. [Nikitina T.P., Kishtovich A.V., Moiseenko E.I. i dr. Issledovanie kachestva zhizni v pediatrii: razrabotka russkoj versii oprosnika PedsQL 4.0 Generic Core Scales dlja ocenki kachestva zhizni detej 8–12 let. Vestnik Mezhnacional’nogo centra issledovanija kachestva zhizni. 2003; 1: 35–44 (in Russian)]
  22. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range, Tadej Battelino, Diabetes Care. 2019; 42 (8): 1593–603. https://doi.org/10.2337/dci19-0028
  23. Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. BMJ. 2002; 324 (7339): 705.
  24. Shestakova M.V., Majorov A.Ju., Filippov Ju.I. i dr. Federal'nye klinicheskie rekomendatsii po pompovoj insulinoterapii i nepreryvnomu monitorirovaniju glikemii u bol'nyh saharnym diabetom. Proekt. Problemy endokrinologii. 2015; 61 (6): 55–78. [Shestakova M.V., Majorov A.Ju., Filippov Ju.I. i dr. Federal’nye klinicheskie rekomendacii po pompovoj insulinoterapii i nepreryvnomu monitorirovaniju glikemii u bol’nyh saharnym diabetom. Proekt. Problemy jendokrinologii. 2015; 61 (6): 55–78 (in Russian)]